Apolipoprotein E polymorphism determines vitamin K supplementation effectiveness in cystic fibrosis patients

J Cyst Fibros. 2018 Jul;17(4):e39-e40. doi: 10.1016/j.jcf.2018.04.007. Epub 2018 May 4.
No abstract available

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Apolipoproteins E / genetics*
  • Cystic Fibrosis* / genetics
  • Cystic Fibrosis* / metabolism
  • Cystic Fibrosis* / therapy
  • Dietary Supplements
  • Female
  • Humans
  • Male
  • Pharmacogenomic Testing
  • Polymorphism, Genetic
  • Treatment Outcome
  • Vitamin K Deficiency* / etiology
  • Vitamin K Deficiency* / prevention & control
  • Vitamin K* / administration & dosage
  • Vitamin K* / pharmacokinetics
  • Vitamins / administration & dosage
  • Vitamins / pharmacokinetics
  • Young Adult

Substances

  • ApoE protein, human
  • Apolipoproteins E
  • Vitamins
  • Vitamin K